66
leisure-time sport activities: position stand from the sections of exercise
physiology and sports cardiology of the European Association of
Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev
Rehabil. - 2011. 18: 446-458.
24. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, et al. The benefits of statins
in people without established cardiovascular disease but with
cardiovascular risk factors: meta-analysis of randomised controlled
trials. BMJ. - 2009. - 338:b2376.
25. Byington RP, Davis BR, Plehn JF, White HD, et al. Reduction of stroke
events with pravastatin: the Prospective Pravastatin Pooling (PPP)
Project. Circulation. - 2001. - 103:387-392.
26. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for
smoking cessation. Cochrane Database Syst Rev. - 2008. 3: CD006103.
27. Center for Disease Control and Prevention [Electronic resource]: How
Tobacco Smoke Causes Disease: The Biology and Behavioural Basis
for Smoking-attributable Disease. A Report of the Surgeon General. -
2010.
-
Availabe
at:
http://www.surgeongeneral.gov/library/
tobaccosmoke/index.html (12.02.2014).
28. Chandola T., Britton A., Brunner E., Hemingway H., Malik M., Kumari M.,
Badrick E., Kivimaki M., Marmot M. Work stress and coronary heart
disease: what are the mechanisms? Eur Heart J. - 2008. 29:640-648.
29. Chen ZM, Jiang LX, Chen YP, Xie JX, et al. Addition of clopidogrel to
aspirin in 45,852 patients with acute myocardial infarction: randomised
placebo-controlled trial. Lancet. - 2005. - 366:1607-1621.
30. Chida Y., Steptoe A. The association of anger and hostility with future
coronary heart disease: a meta-analytic review of prospective evidence.
J Am Coll Cardiol. - 2009. 53:936-946.
31. Claesson M., Birgander L.S., Lindahl B., Nasic S., Astrom M., Asplund
K., Burell G. Women’s hearts-stress management for women with
ischemic heart disease:explanatory analyses of a randomized controlled
trial. J Cardiopulm Rehabil. - 2005. 25:93-102.
32. Clark A.M., Hartling L., Vandermeer B., McAlister F.A. Meta-analysis:
secondary prevention programs for patients with coronary artery
disease. Ann Intern Med. - 2005. - 143:659-672.
33. Clarke R., Halsey J., Lewington S., Lonn E., Armitage J., et al. Effects
of lowering homocysteine levels with B vitamins on cardiovascular
disease, cancer, and cause-specific mortality: meta-analysis of 8
randomized trials involving 37 485 individuals. Arch Intern Med. -
2010. 170:1622-1631.
Klinik protokol Az
ərbaycan Respublikas
ı S
əhiyy
ə Nazirliyinin
İctimai S
əhi
yy
ə v
ə
İslahatlar M
ərk
əzind
ə haz
ırlanm
ış
dı
r.
67
34. Cohen H.W., Gibson G., Alderman M.H. Excess risk of myocardial
infarction in patients treated with antidepressant medications:
association with use of tricyclic agents. Am J Med. - 2000. 108:2-8.
35. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil
H.A., et al. Primary prevention of cardiovascular disease with
atorvastatin in type 2 diabetes in the Collaborative Atorvastatin
Diabetes Study (CARDS): multicentre randomized placebo-controlled
trial. Lancet. - 2004. 364:685-696.
36. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF Heart
Protection Study of cholesterol-lowering with simvastatin in 5963
people with diabetes: a randomised placebo-controlled trial. Lancet. -
2003. 361:2005-2016.
37. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., et al.
Estimation of ten-year risk of fatal cardiovascular disease in Europe:
the SCORE project. Eur Heart J. - 2003. 24:987-1003.
38. Cooney M.T., Dudina A., De Bacquer D., Wilhelmsen L., Sans S., et
al. HDL cholesterol protects against cardiovascular disease in both
genders, at all ages and at all levels of risk. Atherosclerosis. - 2009.
206:611-616.
39. Cossette S., Frasure-Smith N., Lesperance F. Clinical implications of a
reduction in psychological distress on cardiac prognosis in patients
participating in a psychosocial intervention program. Psychosom Med.
- 2001. 63:257-266.
40. Critchley J., Capewell S. Smoking cessation for the secondary
prevention of coronary heart disease. Cochrane Database Syst Rev. -
2004. 1: CD003041.
41. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., et al.
Prevention of cardiovascular events with an antihypertensive regimen
of amlodipine adding perindopril as required versus atenolol adding
bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac
Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a
multicentre randomized controlled trial. Lancet. - 2005. 366:895-906.
42. Dauchet L., Amouyel P., Hercberg S., Dallongeville J.. Fruit and
vegetable consumption and risk of coronary heart disease: a meta-
analysis of cohort studies. J Nutr. - 2006. 136:2588-2593.
43. De Berardis G., Sacco M, Strippoli G.F., Pellegrini F., Graziano G., et
al. Aspirin for primary prevention of cardiovascular events in people
with diabetes: meta-analysis of randomised controlled trials. BMJ. -
2009. 339: b4531.
Klinik protokol Az
ərbaycan Respublikas
ı S
əhiyy
ə Nazirliyinin
İctimai S
əhi
yy
ə v
ə
İslahatlar M
ərk
əzind
ə haz
ırlanm
ış
dı
r.